Who are Zentalis Pharmaceuticals, Inc.'s main suppliers?

Zentalis Pharmaceuticals, Inc. (ZNTL) key suppliers include: RECURIUM-IP-HOLDINGS-LLC, Aprea Therapeutics, Inc., Aprea Therapeutics, Inc., Immunome, Inc.. View the full supplier network at chainsifter.com/chain/ZNTL.

Who are Zentalis Pharmaceuticals, Inc.'s major customers?

Zentalis Pharmaceuticals, Inc. (ZNTL) key customers include: Pfizer Inc., Pfizer Inc., GSK plc, GSK plc, Immunome, Inc. and 2 more. View the full customer network at chainsifter.com/chain/ZNTL.

What sector is Zentalis Pharmaceuticals, Inc. in?

Zentalis Pharmaceuticals, Inc. (ZNTL) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Zentalis Pharmaceuticals, Inc. Suppliers, Customers & Supply Chain (ZNTL)

4Suppliers

7Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Zentalis Pharmaceuticals, Inc. (ZNTL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

13Total relationships

3Distinct source URLs

7High confidence

0.795Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Zentalis Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
RECURIUM-IP-HOLDINGS-LLC	RECURIUM-IP-HOLDINGS-LLC	92%	This payment was made pursuant to a license agreement (the Recurium Agreement) entered into between the Company's wholly owned subsidiary, Zeno Management, Inc. (ZMI), and Recurium IP
APRE	Aprea Therapeutics, Inc.	72%	ates for preclinical and clinical testing, as well as for commercial manufacture if our product candidates receive marketing approval. We require that our CMOs produce active drug substance and finis…
APRE	Aprea Therapeutics, Inc.	72%	Reciprocal relationship from APRE graph: Reciprocal relationship from ZNTL graph: Reciprocal relationship from APRE graph: Reciprocal relationship from ZNTL graph: ates for preclinical and clinical t…
IMNM	Immunome, Inc.	72%	Reciprocal relationship from IMNM graph: Reciprocal relationship from ZNTL graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from ZNTL graph: Reciprocal relationship from IMNM g…

Zentalis Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
PFE	Pfizer Inc.	90%	In April 2022, we entered into a development agreement with Pfizer to collaborate to advance the clinical development of azenosertib
PFE	Pfizer Inc.	90%	Reciprocal relationship from PFE graph: Reciprocal relationship from ZNTL graph: Reciprocal relationship from PFE graph: Reciprocal relationship from ZNTL graph: Reciprocal relationship from PFE grap…
GSK	GSK plc	85%	Reciprocal relationship from GSK graph: Reciprocal relationship from ZNTL graph: In April 2021, we entered into a clinical trial collaboration and supply agreement with GSK under which we have evalua…
GSK	GSK plc	85%	In April 2021, we entered into a clinical trial collaboration and supply agreement with GSK under which we have evaluated the combination of azenosertib
IMNM	Immunome, Inc.	72%	Reciprocal relationship from IMNM graph: be delayed or otherwise adversely affected. ● We may experience delays in completion of our clinical trials based on study design. ● We face substantial compe…
SVB-LEERINK-LLC	SVB-LEERINK-LLC	62%	an adequate level of financing as and when needed to finance our operations on terms acceptable to us or at all, particularly in light of the global macroeconomic environment and fluctuating inflatio…
SVB-LEERINK-PARTNERS-LLC	SVB-LEERINK-PARTNERS-LLC	62%	n light of the global macroeconomic environment, including the ongoing trade tensions between the United States and certain ex-U.S. governments, ongoing military conflicts, and fluctuating inflation …

Zentalis Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ZNTL-DEBT	Debt stack $34.6M	90%	Market cache reports total debt of $34.6M.

Zentalis Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Zentalis Pharmaceuticals, Inc..

Zentalis Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
ZNTL-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 105 tracked holders.

Zentalis Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ARVN	Arvinas, Inc.	100.00	2
BDRX	Biodexa Pharmaceuticals Plc	100.00	2
LIXT	Lixte Biotechnology Holdings, Inc.	100.00	2
DEO	Diageo plc	100.00	2
PCVX	Vaxcyte, Inc.	100.00	2
SMMT	Summit Therapeutics Inc.	100.00	2
APRE	Aprea Therapeutics, Inc.	100.00	1	['supplier']
LEGN	Legend Biotech Corporation	100.00	2
GSK	GSK plc	100.00	1	['customer']
PFE	Pfizer Inc.	100.00	1	['customer']
CTNM	Contineum Therapeutics, Inc.	100.00	2
IMNM	Immunome, Inc.	100.00	1	['customer', 'supplier']
BCAX	Bicara Therapeutics Inc.	100.00	2
PFIZER	PFIZER	60.75	1	['receiving']
SDGR	Schrödinger, Inc.	50.00	2
AMGN	Amgen Inc.	50.00	2
ORANY	ORANGE	50.00	2
GNTA	Genenta Science S.p.A.	50.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	50.00	2
BMY	Bristol-Myers Squibb Company	50.00	2

Zentalis Pharmaceuticals, Inc. Supply Chain